+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis

Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis

Archives of Internal Medicine 162(16): 1849-1858

Background: Initial empirical antimicrobial treatment of patients with community-acquired pneumonia (CAP) is based on expected microbial patterns. We determined the incidence of, prognosis of, and risk factors for CAP due to gram-negative bacteria (GNB), including Pseudomonas aeruginosa. Methods: Consecutive patients with CAP hospitalized in our 1000-bed tertiary care university teaching hospital were studied prospectively. Independent risk factors for CAP due to GNB and for death were identified by means of stepwise logistic regression analysis. Results: From January 1, 1997, until December 31, 1998, 559 hospitalized patients with CAP were included. Sixty patients (11%) had CAP due to GNB, including P. aeruginosa in 39 (65%). Probable aspiration (odds ratio (OR), 2.3; 95% confidence interval (CI), 1.02-5.2; P=.04), previous hospital admission (OR, 3.5; 95% CI, 1.7-7.1; P<.001), previous antimicrobial treatment (OR, 1.9; 95% CI, 1.01-3.7; P=.049), and the presence of pulmonary comorbidity (OR, 2.8; 95% CI, 1.5-5.5; P=.02) were independent predictors of GNB. In a subgroup analysis of P. aeruginosa pneumonia, pulmonary comorbidity (OR, 5.8; 95% CI, 2.2-15.3; P<.001) and previous hospital admission (OR, 3.8; 95% CI, 1.8-8.3; P=.02) were predictive. Infection with GNB was independently associated with death (relative risk, 3.4; 95% CI, 1.6-7.4; P=.002). Conclusions: In our setting, in every tenth patient with CAP, an etiology due to GNB has to be considered. Patients with probable aspiration, previous hospitalization or antimicrobial treatment, and pulmonary comorbidity are especially prone to GNB. These pathogens are also an independent risk factor for death in patients with CAP.

(PDF emailed within 1 workday: $29.90)

Accession: 010349612

Download citation: RISBibTeXText

PMID: 12196083

Related references

Bacteraemic community-acquired pneumonia due to Gram-negative bacteria: incidence, clinical presentation and factors associated with severity during hospital stay. Infection 38(6): 453-458, 2011

Community-acquired pneumonia and Gram-negative bacilli in Cambodia-incidence, risk factors and clinical characteristics. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2018

Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. European Respiratory Journal 35(3): 598-605, 2010

The importance of other classical pyogenic pathogens (Staphylococcus aureus, gram negative bacteria and others) in community acquired pneumonia. Medicina Clinica 110 Suppl 1: 65-70, 1998

Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology 14(1): 105-111, 2008

Risk factors and prognosis of nosocomial pneumonia due to gram-negative bacteria in a general hospital. Revista Espanola de Quimioterapia 13(2): 187-192, 2000

Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli. European Journal of Clinical Microbiology & Infectious Diseases 27(8): 657-661, 2008

Burden and Risk Factors for Pseudomonas aeruginosa Community-acquired Pneumonia: a Multinational Point Prevalence Study of Hospitalised Patients. European Respiratory Journal, 2018

Risk factors for hospital-acquired pneumonia caused by carbapenem-resistant Gram-negative bacteria in critically ill patients: a multicenter study in Korea. Diagnostic Microbiology and Infectious Disease 78(4): 457-461, 2014

Community-acquired, hospital-acquired, and healthcare-associated pneumonia caused by Pseudomonas aeruginosa. Respiratory Medicine Case Reports 12: 30-33, 2014

Community acquired Pseudomonas aeruginosa pneumonia. Connecticut Medicine 63(5): 271-273, 1999

Studies on gram negative bacillary infection part 2 pseudomonas aeruginosa pneumonia. Japanese Journal of Medicine 14(1): 69-70, 1975

Azlocillin--a new penicillin against Pseudomonas aeruginosa and other gram-negative bacteria. Infection 5(3): 170-182, 1977

Nonfermenting gram-negative bacteria and their differentiation from Pseudomonas aeruginosa. Journal of Hygiene, Epidemiology, Microbiology, and Immunology 26(4): 405-416, 1982

RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria. Antimicrobial Agents and ChemoTherapy 59(8): 4750-4758, 2016